Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17079040 | 0.87 | KDM4E (0.51) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078486 | 0.87 | KDM4E (0.51) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078590 | 0.86 | HDAC6 (0.57) | KDM4EALDH1A1MAPT | |
| SCHEMBL20432809 | 0.86 | HDAC6 (0.57) | KDM4EALDH1A1MAPT | |
| SCHEMBL17078484 | 0.85 | KDM4E (0.52) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078587 | 0.84 | MEN1 (0.52) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078639 | 0.84 | KDM4E (0.54) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078453 | 0.82 | MEN1 (0.53) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078485 | 0.82 | SMN1; SMN2 (0.52) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A | |
| SCHEMBL17078761 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2019-05-14 | — | — | US | disclosed |
| EP-3116859-B1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2018-08-01 | — | — | EP | disclosed |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2017-04-06 | — | — | US | disclosed |
| EP-3116859-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015137750-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2015-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287255-B2 | Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | HDAC6, HDAC1, HDAC11 | KDM4E 319/4885SMN1; SMN2 497/4885MAPK1 2398/4885 |
| US-20170096405-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | HDAC6, HDAC1, HDAC5 | KDM4E 468/4885SMN1; SMN2 577/4885MAPK1 2326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.